ARG2 and melanoma: Finally, ourin vitro andin vivo studies validated that targeting Arg2 exacerbated sorafenib-induced ferroptotic melanoma cell death and the antimelanoma activity of sorafenib, indicating that Arg2 expression depletion or activity inhibition may represent a novel strategy for sorafenib therapy of melanoma.